Recombinant h-VEGI as an Anit-Angiogenesis Therapeutic

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$750,197.00
Award Year:
2004
Program:
SBIR
Phase:
Phase II
Contract:
2R44CA103181-02
Agency Tracking Number:
CA103181
Solicitation Year:
2004
Solicitation Topic Code:
n/a
Solicitation Number:
PHS2004-2
Small Business Information
PROTEOMTECH, INC.
PROTEOMTECH, INC., 5980 HORTON ST, STE 405, EMERYVILLE, CA, 94608
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
DANIEL Medynski
(510) 597-9139
MEDYNSKI@PROTEOMTECH-INC.COM
Business Contact:
JOHN BAO
(510) 597-9133
BAO@PROTEOMTECH-INC.COM
Research Institution:
n/a
Abstract
DESCRIPTION (provided by applicant): Blocking or inhibiting tumor blood vessel growth (angiogenesis) remains a critical focal point for anticancer drug development. Studies on Vascular Endothelial Growth Inhibitor (VEGI; TNFSF-15) secreted from human e

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government